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ABSTRACT 
Diabetic nephropathy is one of the most severe microangiopathies of diabetes taking heavy toll on human lives. Diabetic nephropathy is 
characterized by the accumulation of extracelluar matrix protein leading to irreversible decline in renal function and end stage renal disease. 
Incomplete knowledge about molecular mechanism underlying nephropathy limit the use of modern medicines to treat this clinica l entity. 
Moreover, current standard of therapy for diabetic nephropathy mainly focus on reduction in hyperglycemia and hypertension. These therapies 
have limited effect on delaying nephropathy progression. A pressing need for novel therapies initiated studies targeting various molecular 
pathways involved in nephropathic changes. Herbal medicines with beneficial phytochemicals are reported to delay the progression of 
nephropathic changes in diabetes in various experimental studies. This review try to summarize various phytoconstituents proved to be 
effective in management of diabetic nephropathy. The goal is to identify promising phytoconstituents that can be translated into beneficial 
therapeutic options. 
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Introduction 
Diabetes mellitus (DM) is emerging as a serious public health 
concern with major challenges to human health in 21st 
century. Type 2 diabetes has been considered as a global 
pandemic, extending from affluent industrialized countries 
to the developing nation of Asia, Latin America, and Africa1. 
The disease is known to affect 415 million people globally 
and this figure is likely to escalate to 642 million by the year 
20402. The reasons for the considerable increase in type 2 
diabetes in emerging economics are rapid economic 
development, urbanization, nutrition transition and increase 
in sedentary lifestyle3. In India, a recent steep rise in the type 
2 diabetes prevalence makes it considered as “diabetes 
capital of the world”4. 
DM is a chronic metabolic disorder characterized by 
impaired metabolism of carbohydrates, fats and proteins. 
The resulting hyperglycemia is due to decrease utilization of 
carbohydrate and excessive glycogenolysis and 
gluconeogenesis from amino acids and fatty acids5. As 
reported by previous studies, link between muscle insulin 
resistance and predisposition of type 2 diabetes has been 
well established6. The persistent uncontrolled 
hyperglycemia and oxidative stress can lead to serious life 
threatening diabetic complications accounting for significant 
morbidity and mortality7. At microvascular level, chronic 
hyperglycemia commonly induces nephropathy, neuropathy 
and retinopathy8. At macrovascular level, atherosclerosis is a 
common complication resulting in ischemic heart disease, 
cerebrovascular disease and peripheral vascular disease9. 
Diabetic nephropathy 
Diabetic nephropathy (DN) has been identified as an 
important cause of chronic kidney disease. This devastating 
complication occurs in approximately 40% of patients 
suffering from diabetes. Diabetic nephropathy is typically 
characterized by increase in urinary albumin excretion 
(UAE) in the absence of other kidney diseases10. Albuminuria 
is followed by a gradual decline in glomerular filtration rate, 
podocyte loss, progressive glomerular sclerosis and finally 
tubulointerstitial fibrosis11. End stage renal disease (ESRD) 
is most recognizable consequence of DN with significant 
mortality resulting from cardiovascular diseases and 
infection12. The pathophysiology leading to development of 
DN results from diabetes induced disturbance in metabolic 
and hemodynamic pathways13. Polyol pathway, formation of 
advanced glycation end products (AGEs), hexosamine 
pathway, protein kinase C pathway, growth factors, 
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cytokines and free radicals, mitogen activated protein kinase 
(MAPK) activation and poly ADP ribose polymerase (PARP) 
activation have been identified as various pathways playing 
significant role in pathogenesis of DN14. In diabetes, 
excessive glucose influx activates these cellular signaling 
pathway which favors interaction of inflammatory factors. 
This lead to facilitation of inflammatory process and 
subsequently development of glomerulosclerosis15. 
Additionally, generation and circulation of AGEs, release of 
growth factors and hemodynamic and hormonal changes 
lead to release of reactive oxygen species(ROS) and 
inflammatory mediators. These changes lead to glomerular 
hypertension, glomerular hyperfiltration, altered glomerular 
composition and renal hypertrophy. Collectively all these 
renal pathological changes clinically manifested as 
albuminuria and hypertension16. 
In spite of newly developed effective treatment options, DN 
still remain continue to rise. This is because current clinical 
therapies mainly focus on control of hyperglycemia, 
hypertension and inhibition of renin-angiotensin system 
(RAS)17. Currently available drugs such as angiotensin-
converting enzyme inhibitor (ACEI) and angiotensin II 
receptor blockers (ARB) are effective in protecting renal 
function of DN. However, these medicines are not sufficient 
to delay or retard the progression of diabetic nephropathy18. 
Hence, the prime culprit for DN i.e. baseline glycosylated 
heamoglobin remain relatively high. Moreover, high cost and 
associated side effects of modern medicines indicated 
requirement for search of alternative strategies for 
management of diabetes and its complications.  
Role of medicinal plants in management of diabetic 
complications 
Since ancient times natural compounds from plants are 
known to possess medicinal properties and used in treating 
various illnesses. These plants have a vast potential in the 
treatment of medical disorders due to presence of 
therapeutically important phytochemicals 19. Plants such as 
Allium sativum, Eugenia jambolana, Monordica charantia, 
Ocimum sanctum, Phyllanthus amarus, Pterocarpus 
marsupium, Tinospora cordifolia, Trigonella foenum graecum 
and Withania somnifera are found to reduce ill effects of 
diabetes and its secondary complications20. Most of these 
plants enhance the performance of pancreatic tissues by 
increasing the insulin secretion or reducing the intestinal 
absorption of glucose21.  Herbal medicines are cost-effective 
and exhibit improved therapeutic effects with lesser side 
effects. Medicinal plants enriched with flavonoids, alkaloids, 
phenolic compounds, saponins, terpenoids, tannins and 
phytosterol are reported to be effective in the management 
of diabetic complications. These secondary metabolites are 
known to ameliorate persistent hyperglycemia, oxidative 
stress and modulate various metabolic pathways leading to 
diabetic complications7. Although many medicinal plant have 
been reported for anti-diabetic potential only a small 
number of these are proved scientifically for their efficacy22. 
In current days, focus of experimental studies has been 
diverted towards identification of specific plant compound 
with therapeutic potential. Discovery of specific compound 
obtained from various parts of plant help to better 
understand their mechanism of action and future therapeutic 
potential23. Till date numerous plant phytoconstituents have 
been studies for their efficacy in management of DN. In this 
context, this review will provide newer insight on 
phytoconstituents which are natural antioxidant compounds 
and capable of reducing oxidative stress and subsequently 
classical signs of DN. 
Phytoconstituents effective in diabetic 
nephropathy 
Previously conducted studies investigated the effect of 
phytoconstituents on structural and functional changes 
occurring in DN. Different phytochemicals studied in animal 
models are found to exert significant renoprotective effect by 
targeting various molecular pathways. Experimental studies 
highlight the relevance of phytoconstituents as an alternative 
therapeutic option in management of DN. The present 
review provides detailed discussion on the effectiveness of 
scientifically evaluated phyoconstituents. 
Curcumin 
Curcumin, originally isolated from rhizomes of Curcuma 
longa, is widely used herbal remedy and spice. It is an active 
ingredient of turmeric and found to display potent anti-
inflammatory properties24. 
Strong antifibrotic effect of curcumin was reported in 
diabetic nephropathy on db/db mice. Experimental animals 
receiving curcumin for 16 weeks exhibited diminished renal 
hypertrophy, reduced mesangial matrix expansion, and 
lower level of albuminuria. Moreover, curcumin 
administration inhibited the upregulated protein and mRNA 
expression of collagen IV and fibronectin in the renal 
cortices. Additionally, curcumin was associated with 
reduction in mature interleukin-1 and cleaved caspase-1. 
Major renoprotective effect was thought to promote by 
suppression of NOD-like receptor 3 (NLRP3) inflammasome. 
NLR3 are composed of the NLRP3 protein, caspase-1, and the 
adaptor protein apoptosis-associated speck-like protein 
containing a caspase-activating recruitment domain. These 
inflammasome play significant role in development and 
progression of DN25. 
In another experimental study curcumin was found more 
nephroprotective than metformin in attenuating oxidative 
stress in DN. Streptozotocin induced Wistar rats treated with 
curcumin showed regeneration in the form of reduction in 
necrotic and degenerative changes in the tubular and 
glomerular epithelium. Additionally, curcumin produced low 
tubular epithelial hypertrophy and inflammatory cells 
infiltration. Nephroprotective effect of curcumin is 
considered due to reduction in oxidative stress as exhibited 
by normalization of oxidative enzymes level26. These 
preclinical study results warrant further testing of curcumin 
in clinical setting as a treatment for DN. 
Quercetin 
Quercetin (3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-
chromen-4-one) is potent dietary flavonoid frequently found 
in onion, apple, berries, nuts, seeds, barks, flowers, tea, 
brassica vegetables and leaves27. Quercetin shows a broad 
range of pharmacological activities and act as a potent 
antioxidant28. 
Treatment with quercetin in streptozotocin induced diabetic 
rats showed improvement in renal function over 12 weeks 
period. Administration of quercetin attenuated the 
overexpression of transforming growth factor-1 (TGF-1) 
and connective tissue growth factor (CTGF) involved in 
pathophysiological mechanism of DN29.Renoprotective 
significance of quercetin was also demonstrated in DN 
associated with hypercholesterolemia. Another team of 
researchers studied effect of low-dose quercetin for 6 weeks 
in streptozotocin induced diabetic rat model where diabetes 
was associated with dyslipidemia. Quercetin was found to 
significantly reduce DN by inducing biochemical changes 
such as decrease in glucose and triglyceride serum levels and 
reduction of glomeruloscelrosis. Quercetin is known to 
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exhibit high antioxidant activity, long half-lives, high 
mitochondrial permeability, ability to suppress pro-oxidant 
enzymes and stimulation of antioxidant enzymes. All these 
qualities make quercetin as an ideal candidate for 
nephroprotection in DN30. 
Treatment with quercetin in a rat model of adenine-induced 
chronic kidney disease leads to improvement in renal 
function. This was accompanied with reduced oxidative 
stress factors, decreased renal inflammation and reduction 
in renal tubular damage. Quercetin treatment regulated the 
expression of fibroblast growth factor 23 (FGF23) and 
parathyroid hormone and subsequently regulated levels of 
calcium and phosphorus in the body31. 
Mangiferin 
Mangiferin (2--D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-
xanthen-9-one) is a xanthone derived from higher plants and 
mango fruits32. Several lines of investigation exhibited its 
pharmacological activities including antioxidant effects, anti-
inflammatory, antidiabetic and immunomodulatory activities 
33. 
Nephroprotective effect of mangiferin was investigated in 
STZ induced diabetic nephropathy by inhibition of oxidative 
stress and protection of cells from apoptotic death. 
Magniferin treatment efficiently reduced the alterations in 
the markers of nephrotoxicity including serum urea, 
creatinine and uric acid level. Magniferin was found to 
improve the changes of diabetic renal injury such as 
reduction in the size of glomerulus and decrease in the 
hydropic changes in the proximal convoluted tubules. This 
renoprotective effect against oxidative injury was thought to 
be develop by modulating various pathways including ROS-
induced PKCs, MAPKs, NF-kB and TGF-1 mediated and 
TNF related mitochondrial dependent apoptotic 
pathways34. 
Mangiferin was demonstrated to delay the progression of DN 
and protected podocyte in STZ-induced diabetic rats by 
modulating various pathways. Treatment with mangiferin in 
diabetic rats was found to significantly reduced albuminuria, 
inhibited glomerular extracellular matrix expansion and 
restored the expression of nephrin, a podocyte marker. 
Previous studies suggested role of podocyte injury in 
development of progressive proteinuria in DN. Podocytes are 
highly specialized, terminally differentiated cells in 
glomeruli. These cells are unable to differentiate and 
autophagy process maintains the structure and function of 
podocytes. Impairment in autophagy leads to podocyte loss 
and subsequently proteinuria in DN. Magniferin was found to 
promote autophagy as exhibited by the up-regulation of LC3 
II and the down-regulation of p62 in both DN rats and 
podocytes. It is also noted that mangiferin increased the 
number of autophagosomes in the podocytes by up-
regulating AMPK phosphorylation and p-ULK1 and down-
regulation of mTOR phosphorylation35. 
Treatment with magniferin significantly ameliorated renal 
dysfunction as exhibited in another study. Magniferin 
efficiently reduced serum AGEs level, malondialdehyde 
(MDA) and 24 hours albuminuria in rat model. It 
significantly increased an activity of superoxide dismutase 
(SOD) and glutathione peroxidase (GSH) and creatinine 
clearance rate. Magnifierin inhibited glomerular extracellular 
matrix expansion and accumulation and reduced 
overexpression of TGF-1 in glomeruli36. Similarly, beneficial 
renoprotective effect of magniferin was evaluated in a rat 
model by up-regulating glycoxalase 1 ,a detoxifying enzyme 
of methylglyoxal ( a precursor of AGEs).In this study, 
magniferin was found to reduce levels of AGEs and mRNA 
expression of their receptor (RAGE) in the renal cortex of 
diabetic rat and ameliorated progression of DN. However, 
magniferin failed to produce reduction in blood glucose and 
body weight in experimental rats37. 
Berberine 
Beberine (BBR) is the most active alkaloid belonging to the 
structural class of protoberberines. It has been commonly 
used as a non-prescription drug for management of diarrhea, 
dysentery, stomatitis and hepatitis38. BBR can be derived 
from plants such as Coptis chinesis (Coptis or Goldthread), 
Hydrastis Canadensis (Goldenseal), Berberis aquifolium 
(Oregon grape),Berberis aristata (Tree Turmeric), Berberis 
vulgaris (Barberry) and Arcangelisia flava 39. 
Therapeutic potential of BBR was elucidated in DN in STZ 
induced diabetic rat model. Treatment with BBR significantly 
attenuated renal histological injuries due to inhibition of 
renal inflammation associated with inactivation of nuclear 
factor kappa-light-chain-enhancer of activated B-cell 
signaling. Subsequently, this blocked upregulation of pro-
inflammatory cytokines (interleukin-1, tumour necrosis 
factor-) and chemokine (monocyte chemotactic protein-1). 
BBR administration was also found to inactivate TGF-
/Smad 3signalling and suppressed renal fibrosis, including 
expression of fibronectin, collagen I and collagen IV40.                  
Potential application of berberine was proved in diabetic 
nephropathy in experimental model. Berberine 
administration in STZ induced DN rats attenuated the 
systemic and renal cortex inflammatory response and 
podocyte apoptosis. Machanistic analysis concluded the role 
of berberine in lowering HG-induced apoptosis of podocytes 
by inactivating TLR4/NF-kB pathway41. Similarly, in another 
study BBR improved renal function in diabetic rats by down-
regulating inflammatory molecules. BBR significantly 
reduced diabetic-induced increase of TNF- and II 6 and 
inhibited macrophage infiltration42. 
Beneficial role of BBR was also documented in inhibition of 
DN induced renal fibrosis. Treatment with BBR significantly 
reduced kidney injury and expression levels of TGF-, 
vimentin and -smooth muscle actin (-SMA) suggesting 
importance of BBR in management of renal fibrosis43. 
Another study investigated the renoprotective mechanism of 
BBR by improvement in the abnormal changes in the matrix 
metalloproteinases/tissue inhibitor of matrix 
metalloproteinases (MMPs/TIMPs) system. Also BBR 
administration reduced TGF-1, fibrinectin and type IV 
collagen expression levels. All these collectively inhibited 
accumulation of extracellular matrix and ameliorated 
symptoms of DN44. 
Emodin 
Emodin is an anthraquinone polyphenol present in medicinal 
herbs 45.It is commonly derived from Chinese medicinal 
herbs such as Rheum palmatum, Polygonum cuspidatum and 
Polygonum multiflorum46. 
Protective effect of emodin was recorded in high glucose 
(HG) induced podocyte epithelial-to-mesenchymal transition 
(EMT) pathway. Emodin was found to efficiently inhibit 
integrin-linked kinase inhibitor, reduce desmin expression 
and partially restored nephrin expression in HG-stimulated 
podocyte. Thus, emodine ameliorated HG induced EMT and 
correct podocyte dysfunction and albuminuria47. 
In another study emodine was demonstrated to control renal 
inflammation and modulate various pathways involved in 
DN pathogenesis in STZ induced diabetes. Emodine was 
found to efficiently inhibit inflammation-related factors and 
oxidative stress. Moreover, it suppressed the expression of 
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intercellular adhesion molecule 1(ICAM-1) and B-cell 
lymphoma 2-associated X protein (Bax).It also lead to 
activation of phosphorylated Akt and phosphorylated 
glucogen synthase kinase 3 (p-GSK-3) expression48. 
Endoplasmic reticulum (ER) stress is cytotoxic and 
associated with podocyte apoptosis, thus play vital role in 
pathogenesis of DN. Emodin treatment in experimental mice 
decreased the expression of signaling pathways involved in 
ER stress including phosphorylated protein kinase RNA-like 
endoplasmic reticulum kinase (P-PERK) and phosphorylated 
eukaryotic initiation factor 2 (P-eIF2) in both in vivo and 
in vitro. Thus emodin exert renoprotective action by 
inhibiting podocyte apotosis in DN49.Furthermore, emodine 
efficiently provided protection in renal dysfunction by 
inhibiting expressions of phosphorylated mitogen activated 
protein kinase 38 (p38 MAPK) and downregulation of the 
expression of fibronectin. This decreased average kidney 
weight to body weight ratio, glomerular area and glomerular 
volume along with reduction in biochemical parameters50. 
Luteolin 
Luteolin (2-3,4-fihydroxyphenyl-5,7-dihydroxy-4-
chromenone) is a naturally occurring flavonoid present in 
fruits and vegetables 51.Edible plants such as pepper, celery, 
carrot and spinach are enriched with luteolin52. Plants 
enriched with luteolin form an important part of Chinese 
traditional medicine. It is well-known for its antioxidant or 
pro-oxidant function that produces multiple biological 
effects 53. 
Wang et al in their experimental study concluded that 
luteolin administration prevented the morphological 
destruction of the kidney and regulated redox balance due to 
its direct antioxidant activity. Treatment with luteolin in 
STZ-induced diabetic rats showed improvement in clearance 
of blood urea and creatinine by kidney. Moreover, luteolin 
was found to reduce MDA level and increase SOD activity, 
suggesting its role in reducing oxidative stress in diabetes54. 
Luteolin was found to restore STZ-induced insulin 
resistance, dyslipidemia, hyperuricemia and renal 
inflammatory cell infiltration in experimental mice. This 
action was thought to be due to inhibition of RIP 140/NF-kB 
pathway and improvement in insulin signaling pathway.NF-
kB is ubiquitous transcription factor responsible for 
regulating the expression of genes, which mediated 
production of inflammatory cytokines, chemokines and 
adhesion molecules. Lutolin induced inhibition of this 
pathways regulated inflammatory process in renal cells 
providing renoprotective effect55. 
Thymoquinone 
Thymoquinone (TQ) is a monoterpene molecule, chemically 
known as 2-methyl-5-isopropyl-1,4-benzoquinone56. This 
bioactive compound is obtained from black seed (Nigella 
sativa) oil. It is a spice found in the Mediterranean region and 
in Western Asia countries including India, Pakistan and 
Afghanistan57. 
Kanter found that treatment with thymoquinone in STZ 
induced diabetic rat lead to renal morphological and 
functional improvement. Thymoquinone effectively reduced 
glomerular size, thickening of capsular, glomerular and 
tubular basement membranes. It increased amount of 
mesangial matrix and tubular dilation and renal function 
indicating its usefulness in DN58. 
Sayed investigated effect of thymoquinone and 
proanthocyanidin and combination of both in reducing 
oxidative stress in experimental model of DN. Both were 
found to efficiently reduced the elevated levels of IL-6,an 
inflammatory cytokines involved in thickening of glomerular 
basement membrane and proliferation of mesangial cells and 
increased endothelial permeability. Reduction in IL-6 
subsequently lead to decrease in serum urea and creatinine 
level. Both were found to effectively increased levels of 
glutathione (GSH) and superoxide dismutase (SOD) activity 
with reduction in lipid peroxidation and NO level. This 
suggested potential antioxidant impact of thymoquinone in 
DN 59. 
TQ found to offer protective effects in experimental DN by 
attenuating renal morphological and immunohistochemical 
changes in STZ-diabetic rats. TQ treatment reduced 
glomerular size, decreased thickening of capsular glomerular 
and tubular basement membranes and mesangial matrix and 
decreased tubular dilatation and cast formation. 
Immunohistochemical studies confirmed protective TQ 
effect by exhibiting moderate expression of ZO-1(an 
epithelial marker in glomeruli) and low or absent expression 
of FspI, desmin and MMP-17 (mesenchymal markers in 
glomeruli and tubules).These results suggested recovery of 
podocyte and tubular epithelial-mesenchymal transition 
(EMT) in diabetic rat with TQ treatment60. 
Trigonelline 
Trigonelline (TRIG), chemically known as N-methylnicotinic 
acid (C7H7 NO2), is a major alkaloid component commonly 
derived from fenugreek (Trigonella foenum-graecum)61. This 
polar hydrophilic alkaloid can also be extracted from Allium 
sepapea, Coffea sp, Pissum sativum, Glycine max and 
Lycopersicon esculentum. It is well-known for its biological 
activities giving protection against hyperglycemia and 
hypercholesterolemia62. 
Role of trigonelline was investigated in diabetic hypertensive 
nephropathy in neonatal diabetic (nSTZ) rat model. 
Trigonelline was found to be effective in suppressing 
oxidative stress in kidney and reduced renal cell apoptosis. It 
improved renal function as indicated by reduction in serum 
creatinine and BUN levels and enhancement in glomerular 
filtration rate. The treatment group exhibited alleviation in 
the degenerative changes in kidney tissue and fibrosis63. 
Administration of trigonelline along with sitagliptin (SITA) in 
experimental rat model found to prevent structural kidney 
damage and development of DN. Concomitant administration 
of TRIG and SITA was found to reduce renal oxidative stress 
by reducing MDA content and increasing SOD and GSH 
concentration, suggesting development of defense 
mechanism against free radicles 64. 
Naringenin 
Naringenin is aglycone of naringin belong to series of citrus 
flavonoids65. This naturally occurring flavonone is mainly 
found in grapefruit and oranges. It exhibits diverse biological 
activities including antidiabetic, immunomodulatory, anti-
inflammatory, DNA protective and antioxidant effects66. 
Nephroprotective effect of naringenin was found to be 
associated by ameliorating kidney injury via regulating let-
7a/TGFBR1 signaling. Naringenin upregulated let-7a in 
mesangial cells affecting expression of Co14 and FN, thus 
inhibiting excessive mesangial cells 
proliferation.Additionally,let-7a is negatively regulated the 
expression of TGFBR1 which is required for downregulation 
of TGF-1/smad signaling. Thus, naringenin inhibited TGF-
/smad signaling activation by upregulating let-7a67. 
Protective effect of naringenin was demonstrated in diabetic 
renal impairment by altering oxidative stress, modulating 
cytokines expression and apoptotic events. Naringenin 
administration in diabetic rat significantly lead to reduction 
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of MDA levels and increase of  SOD, GSH and catalase levels 
in diabetic kidney. It also lead to reduction of apoptotic 
activity and expression of TGF-1 and IL-1 that help to 
ameliorate structural alterations in the kidney tissues68. 
In diabetic mice, naringenin treatment dose-dependently 
reduced renal TNF- level. It was effective in reducing 
production of IL-1,Il-6 and monocyte chemoattractant 
protein-1.With increased dose, naringenin reduced 
production of type IV collagen, fibronectin and TGF-1.It was 
effective in reducing protein kinase c activity, suppressed 
NF-k p65 activity, mRNA expression and protein 
production in kidney. Thus, naringenin exert renoprotective 
effect due to its anti-inflammatory and anti-fibrotic effects69. 
Hesperidin 
Hesperidin is a member of flavanone group of flavonoids 
largely derived from citrus fruits70. It offers widespread 
health application due to its antioxidant and anti-
inflammatory actions71. 
Jain et al found nephroprotective effect of hesperidin in early 
DN in experimental type 2 diabetic rats associated with 
antioxidant property. It was found to effectively revere 
creatinine clearance and attenuated hyperfiltration 
suggesting its role in prevention of progression of early DN. 
Moreover, it was found to be effective in restoring structural 
changes in kidney including thickening of basement 
membrane and mesangial expansion72..Another study 
explored the renoprotective role of hesperidin by 
suppressing TGF-1-ILK-Akt signaling pathway. 
Administration of hesperidin for 4 weeks regulated blood 
glucose level and impaired glucose tolerance ability in 
diabetic mice. It normalized pathological abnormalities in 
renal tissues including distortion in glomerular basement 
membrane and expanded mesangial regions. Also, it repaired 
podocyte function by increasing renal nephrin expression 
and decreasing renal alpha smooth muscle actin expression. 
This effect was considered due to hesperidin induced 
inhibition of expression of TGF-1 and downstream effector 
integrin-linked kinase and Akt73. 
Aliskiren 
Aliskiren is an orally active nonpeptide direct renin inhibitor, 
which plays pivotal role in DN by blocking renin-
angiotensin-aldosterone system (RAAS)74. Chemically 
aliskiren is known as 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-
methylpropyl)-5-amino-4-hydroxy-2,7 diisopropyl-8-(4-
methoxy-3-[3-methoxypropoxyl-]phenyl)-octanamide75. 
Renin is rate-limiting enzyme of the renin-angiotensin 
system (RAS).It generates angiotensin I and signals through 
the (pro)renin receptor (p)RR to exert angiotensin II-
independent effects. This plays major role in damaging renal 
cells in DN. Aliskiren was found to effectively alleviated 
albuminuria and glomerulosclerosis. Morphologically, it was 
found to be effective in reducing thickening of the 
glomerular basement membrane and reduced podocyte loss. 
It ameliorates diabetic renal injury by compensatory 
increase in renin in the glomeruli due to blockage of the 
negative feedback loop and partially suppressed the 
intracellular signaling mediated via receptor (p)RR activated 
in hyperglycemia76. Clinically, renoprotective effect of both 
aliskiren monotherapy and in combination with 
pentoxifylline was demonstrated in patients with DN. 
Monotherapy with aliskiren showed significant 
antiproteinuric effect by reducing urinary albumin excretion 
(UAE).Effect is due to aliskiren induced inhibition of the rate-
limiting step in the RAS (conversion of angiotensinogen to 
ANG I via renin).Thus, aliskiren is effective as renoprotective 
agent by blocking generation of angiotensin II completely 
and inhibiting effects produced via activation of (p)RR. 
Similarly, aliskiren found to reduce serum creatinine level by 
inducing complete blockage of Ang II generation and 
inhibition of (p)RR effects77. 
Renoprotective role of aliskiren was also recorded in 
another clinical study involving type 2 diabetic patients with 
insufficient blood pressure control. Administration of 
aliskiren (300 mg) in combination with losartan reduces 
albuminuria of DN independent of baseline blood pressure78. 
Myricetin 
Myricetin is a plant derived flavonoid, well-known for its 
neutraceutical properties79. It is commonly consumed as a 
part of human diet through fruits, vegetables, tea, berries 
and red wine80. 
An experimental study found improvement in altered renal 
functions and restoration of renal activities in DN with 
myricetin treatment. Myricetin administration in STZ-
induced diabetic rat efficiently decreased glomerulosclerosis 
and reduced BUN and proteinuria. It also found to improve 
creatinine clearance and restored altered renal activities of 
glutathione peroxidase (GPx) and xanthine oxidase (XO)81 
Myricetin was found to produce remarkable 
nephroprotection in STZ-cadmium induced diabetic 
nephrotoxicity in rat model. Structurally, myricetin 
suppressed extracellular mesangial matrix expansion, 
glomerulosclerosis and interstitial fibrosis in nephrotoxic 
rats. It was demonstrated that myricetin suppressed sterol 
regulatory element binding protein-1a (SREBP-1a), SREBP-
1c,SREBP-2, TGF-1 and vascular endothelial growth factor 
(VEGF). It also upr 
egulated peroxisome proliferator-activated receptor alpha 
(PPAR-) protein expression82. 
Apigenin 
Apigenin (4,5,7,-trihydroxyflavone) is a yellow crystalline 
powder belonging from flavone class83.This bioactive 
flavonoid is widely investigated for antioxidant, anti-
inflammatory and anticancer properties84. 
Apigenin was found to halt the development and progression 
of DN in experimental model by suppressing oxidative stress 
and fibrosis. When apigenin in dose of 20mg/kg was 
administered in STZ-induced diabetic rat, it attenuated renal 
dysfunction, oxidative stress and fibrosis by inhibiting MAPK 
pathways. Apigenin was recorded to reduce TGF-1, 
fibronectin and type IV collagen. Apigenin prevented MAPK 
activation which subsequently inhibited inflammation by 
reducing TNF-, IL-6 and NF-kB expression. Inhibition of 
MAPK lead to reduction in apoptosis by increasing 
expression of Bcl-2 and decreased Bax and caspase-
385.Apigenin administration in diabetic rats normalized the 
deterioration in kidney by reversing swelled Bowman’s 
capsule of kidneys, damaged glomeruli and nephritic cells86. 
Paeoniflorin 
Paeoniflorin (PE) is the active component of Paeonia 
lactiflora Pall or Paeonia veitchil Lynch87. PE is monoterpene 
glycoside, the -glucoside of paeoniflorigenin. It is commonly 
used in Chinese Traditional Medicine88. 
Investigational studies showed that PE prevented the 
progression of DN by modulating inflammatory process.PE 
was found to be efficient in normalizing urinary albumin 
creatinine ratio. Also, it significantly suppressed glomerular 
hypertrophy, expression of TGF-, type IV collagen, 
intracellular adhesion molecule 1 and renal infiltration of 
macrophages89. Likewise, PE is noted to have therapeutic 
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potential for DN by mediating anti-inflammatory actions. 
Toll-like receptors (TLRs) are involved in pathogenesis of DN 
by promoting inflammation.12 weeks intraperitoneal 
injection of paeoniflorin efficiently reduced albuminuria with 
restoration of renal histopathology. Paeoniflorin was 
effective in reducing macrophage infiltration with reduced 
expression of TLR2 signaling pathway biomarkers90. 
Similarly, anti-inflammatory and immuneregulatory 
mechanism of PE was evaluated in both in vivo and in vitro 
studies. In vivo, PE could reduce albuminuria and inhibited 
macrophage infiltration and activation through blockage of 
the TLR2/4 signaling pathway. In vitro, PE reduced the AGEs-
induced TLR2/4 activation and subsequently controls 
inflammatory responses91.  
12 weeks treatment with paeoniflorin restored functional 
and histological damage to kidney. In this study, PE exerted 
renoprotective effect with reduction of macrophage 
infiltration and inflammatory factor expression. Additionally, 
PE was effective in suppressing Janus kinase (JAK)2/signal 
transducer (STAT)3 signaling pathway which regulates a 
broad range of biological effects including cell proliferation, 
differentiation, inflammation and apoptosis92. 
 
Table 1: Phytoconstituents with mechanism of action 
S. No Phytoconstituents Targeted metabolic pathway/Mechanism of action Ref 
1 Curcumin  Suppression of NOD-like receptor 3 (NLRP3) inflammasome 
 Reduction in oxidative stress 
25 
26 
2  Quercetin  Attenuatation of overexpression of TGF-1 and CTGF 
 Exhibit high antioxidant activity 
29 
30 
3 Mangiferin 
 
 Modulation of ROS-induced PKCs, MAPKs, NF-kB and TGF-1 mediated and TNF related 
mitochondrial dependent apoptotic pathways 
 Promote autophagy by the up-regulation of LC3 II and the down-regulation of p62 and 
increase  the number of autophagosomes in the podocytes by up-regulating AMPK 
phosphorylation and p-ULK1 and down-regulation of mTOR phosphorylation 
34 
 
35 
4 Berberine 
 
 Inactivate TGF-/Smad 3 signalling and suppressed renal fibrosis, including expression 
of fibronectin, collagen I and collagen IV 
 Lowering of HG-induced apoptosis of podocytes by inactivating TLR4/NF-kB pathway 
40 
 
41 
5 Emodin 
 
 Inhibit integrin-linked kinase inhibitor, reduce desmin expression and partially restored 
nephrin expression in HG-stimulated podocyte 
 Suppression of the expression of ICAM-and Bax-protein, activation of phosphorylated Akt 
and p-GSK-3 expression 
47 
 
48 
6 Luteolin 
 
 Reduction of oxidative stress 
 Inhibition of RIP 140/NF-kB pathway and improvement in insulin signaling pathway 
50 
55 
7 Thymoquinone 
 
 Reduction of oxidative stress 
 Moderate expression of ZO-1and low or absent expression of FspI, desmin and MMP-17 
59 
60 
8 Trigonelline  Suppression of oxidative stress 63 
9 Naringenin  Inhibition of TGF-/smad signaling activation by upregulating let-7a 
 Reduction of oxidative stress 
67 
68 
10 Hesperidin  Antioxidant property 72 
11 Aliskiren  Blocking renin-angiotensin-aldosterone system 73 
12 Myricetin 
 
 Restored altered renal activities of glutathione peroxidase (GPx) and xanthine oxidase 
(XO) 
 Suppressed SREBP-1a,SREBP-1c,SREBP-2, TGF-1 and VEGF and  upregulated PPAR- 
protein expression 
81 
 
82 
13 Apigenin 
 
 Prevented MAPK activation which subsequently inhibited inflammation by reducing 
TNF-,IL-6 and NF-kB expression and reduction in  apoptosis by increasing expression of 
Bcl-2 and decreased Bax and caspase-3 
85 
14 Paeoniflorin 
 
 Reduction in macrophage infiltration with reduced expression of TLR2 signaling pathway 
biomarkers 
 Reduction in AGEs-induced TLR2/4 activation and control of inflammatory responses 
 Suppression of Janus kinase (JAK)2/signal transducer (STAT)3 signaling pathway 
90 
 
91 
92 
15 Rutin 
 
 Reduction in expression of AGEs, collagen IV, laminin, TGF-1,p-Smad 2/3 and CTGF 
 Inhibition of expression of ACTA2 and p38 
96 
97 
16 Allicin  Inhibition of expression of collagen I,TGF-1 and p-ERK ½ 100 
 
Rutin 
Rutin, chemically known as 3,3,4,5,7-pentahydroxyflavone-
3-rhamoglucoside,is a flavonoid abundantly present in plant 
kingdom93. This vital nutritional component of diet is 
commonly found in passion flower, buckwheat, tea and 
apple94. It offers diverse range of pharmacological 
application due to its significant antioxidant property95. 
Nephroprotective effect of rutin was proved in a clinical 
study involving patient with long-term diabetes mellitus. 
Administration of rutin supplementation tablets over period 
of 120 days decreased serum levels of urea and creatinine, 
which minimizes the risk of kidney damage and failure34. 
10 weeks oral administration of rutin prevented 
development of DN in STZ induced diabetic rats. Hers, rutin 
decreased the levels of FBG, serum creatinine, urine protein 
and BUN. It also reduced expression of AGEs, collagen IV, 
laminin, TGF-1,p-Smad 2/3 and connective tissue growth 
factor (CTGF).Thus, rutin offered renoprotective effect by 
inhibiting proliferation of mesangial cells and decreased 
thickness of glomerular basement membrane96. Protective 
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effect of rutin was also proved on high-glucose-induced 
mesangial cell group. Actin,2,smooth muscle, aorta (ACTA2) 
is an important protein required for the contraction of 
vascular smooth muscle cell.p38 is a key component of 
mitogen-activated protein kinase-mediated signaling 
pathway involved in proliferation, apoptosis and 
inflammation. High glucose induced mesangial cells showed 
increased expression of both ACTA2 and p38.Rutin 
administration significantly inhibited expression of both 
ACTA2 and p38. It also inhibited glucose induced cell viability 
and ATP content and thus regulated cell cycle progression in 
mesangial cells97. 
Allicin 
Allicin (allyl 2-propenethiosulfinate or diallylthiosulfinate ) 
is the principle bioactive compound present in garlic (Allium 
sativum L.)98. It is produced during tissue damage from non-
proteinogenic amino acid alliin (S-allylcysteine sulfoxide) in 
a reaction catalyzed by the enzyme alliinase. Presence of 
thiosulfinate makes allicin as a reactive sulfur species 
(RSS).It undergoes a radox-reaction with thiol groups in 
glutathione and protein which is responsible for diverse 
range of biological activities99. 
12 weeks treatment with allicin induced protective effect on 
renal damage in STZ diabetic rats. Allicin reduced altered 
biochemical parameter in DN including FBG, BUN, serum 
creatinine and albuminuria. It inhibited expression of 
collagen I, TGF-1 and phosphorylated extracellular signal-
regulated kinase ½ (p-ERK ½). These results were 
associated with recovery in morphological alterations of the 
kidney in DN with allicin treatment100. 
Conclusion 
In summary, results obtained from various experimental 
studies revealed that use of phytoconstituents in DN 
improves biochemical markers and antidiabetic cellular 
mechanism. Our incipient understanding about beneficial 
effect of phytoconstituents in DN indicate requirement of 
further experimental studies exploring mechanism of action, 
effectiveness and safety in details. 
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